{"id":2408,"date":"2026-03-21T18:00:00","date_gmt":"2026-03-21T18:00:00","guid":{"rendered":"https:\/\/livingdiabetes.com\/?p=2408"},"modified":"2026-03-11T01:53:35","modified_gmt":"2026-03-11T01:53:35","slug":"sglt2-inhibitors-heart-and-kidney-protection-beyond-blood-sugar","status":"publish","type":"post","link":"https:\/\/livingdiabetes.com\/ur\/sglt2-inhibitors-heart-and-kidney-protection-beyond-blood-sugar\/","title":{"rendered":"SGLT2 Inhibitors: Heart and Kidney Protection Beyond Blood Sugar"},"content":{"rendered":"
\n

SGLT2 inhibitors represent one of the most transformative developments in diabetes medicine in the past decade. Originally approved as glucose-lowering agents, these medications have since demonstrated remarkable protective effects on the heart and kidneys \u2014 benefits so significant that they are now recommended for people with heart failure and chronic kidney disease even in the absence of diabetes.<\/p>\n<\/div>\n

How SGLT2 Inhibitors Work<\/h2>\n

Sodium-glucose cotransporter-2 (SGLT2) inhibitors work by blocking the SGLT2 protein in the kidney’s proximal tubule, which is responsible for reabsorbing approximately 90% of filtered glucose back into the bloodstream. By inhibiting this transporter, SGLT2 inhibitors cause the kidneys to excrete excess glucose in the urine \u2014 effectively lowering blood sugar without stimulating insulin secretion.<\/p>\n

This mechanism also produces several secondary effects: a modest reduction in blood pressure (through osmotic diuresis and natriuresis), weight loss (due to caloric loss through glycosuria), and a reduction in intraglomerular pressure (which protects the kidneys from hyperfiltration damage).<\/p>\n

The Landmark Cardiovascular and Renal Outcome Trials<\/h2>\n\n\n\n\n\n\n\n\n
Trial<\/th>\nDrug<\/th>\nKey Finding<\/th>\n<\/tr>\n<\/thead>\n
EMPA-REG OUTCOME (2015)<\/strong><\/td>\nEmpagliflozin<\/td>\n38% reduction in CV death; 35% reduction in heart failure hospitalisation<\/td>\n<\/tr>\n
CANVAS (2017)<\/strong><\/td>\nCanagliflozin<\/td>\n14% reduction in MACE; significant reduction in heart failure hospitalisation<\/td>\n<\/tr>\n
DAPA-HF (2019)<\/strong><\/td>\nDapagliflozin<\/td>\n26% reduction in worsening heart failure or CV death \u2014 in patients with and without diabetes<\/td>\n<\/tr>\n
CREDENCE (2019)<\/strong><\/td>\nCanagliflozin<\/td>\n30% reduction in kidney failure, dialysis, or renal death in diabetic kidney disease<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\u26a0\ufe0f Important Side Effects to Know<\/strong><\/p>\n